NASDAQ
19.09.25 | 22:00
6,200 US-Dollar
-2,21 % -0,140
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.09. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum | 3 | GlobeNewswire (USA) | ||
| 05.09. | H.C. Wainwright reiterates Buy rating on Cullinan Oncology stock at $24 | 3 | Investing.com | ||
| 04.09. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.08. | Cullinan Oncology stock gets Buy rating from H.C. Wainwright ahead of WCLC data | 2 | Investing.com | ||
| 21.08. | Cullinan Oncology: H.C. Wainwright startet Coverage mit "Buy" vor wichtigen Studiendaten | 3 | Investing.com Deutsch | ||
| 07.08. | Cullinan Therapeutics GAAP EPS of -$1.07 | 2 | Seeking Alpha | ||
| 07.08. | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results | 175 | GlobeNewswire (Europe) | CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease BCMA-directed bispecific T cell engager velinotamig... ► Artikel lesen | |
| 07.08. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.07. | Cullinan Oncology stock rating reiterated at Buy by Clear Street | 10 | Investing.com | ||
| 12.06. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.06. | Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio | 1 | Contract Pharma | ||
| 04.06. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases | 171 | GlobeNewswire (Europe) | Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with... ► Artikel lesen | |
| 04.06. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.05. | Cullinan Therapeutics, Inc.; Taiho Pharmaceutical Co., Ltd.; Taiho Oncology, Inc.: Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 | 1 | GlobeNewswire (USA) | ||
| 08.05. | Cullinan Therapeutics GAAP EPS of -$0.74 beats by $0.07 | 1 | Seeking Alpha | ||
| 08.05. | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.05. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results | 846 | GlobeNewswire (Europe) | Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren's... ► Artikel lesen | |
| 29.04. | Cullinan Therapeutics startet Studie zur Sjögren-Krankheit | 3 | Investing.com Deutsch |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ENLIVEN THERAPEUTICS | 18,960 | -4,84 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| HUMACYTE | 1,860 | +3,91 % | Humacyte Plans To File IND For Coronary Tissue Engineered Vessel In Q4 | ||
| RECURSION PHARMACEUTICALS | 4,910 | -0,41 % | Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances | ||
| NUVALENT | 76,64 | -5,34 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| 89BIO | 14,860 | -0,67 % | Milliarden-Pharma-Übernahme: Roche kauft sich in Biotech-Milliardenmarkt ein - 89bio im Fokus | © Foto: SOPA Images - Sipa USARoche kauft das US-amerikanische Biotech-Unternehmen 89bio für bis zu 3,5 Milliarden US-Dollar. Im Fokus steht ein Hoffnungsträger gegen die Fettleberkrankheit MASH, ein... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 41,090 | -1,72 % | Roth/MKM initiates Avidity Biosciences stock with Buy rating on platform potential | ||
| SUMMIT THERAPEUTICS | 18,860 | -1,92 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
| ADMA BIOLOGICS | 15,910 | -1,55 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 49,130 | -3,97 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses | ||
| APOGEE THERAPEUTICS | 36,450 | -5,15 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 55,00 | +1,78 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,300 | -1,43 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,180 | -4,85 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| TOURMALINE BIO | 47,700 | +0,04 % | BMO Capital downgrades Tourmaline Bio stock rating following Novartis acquisition news | ||
| VERA THERAPEUTICS | 25,600 | -2,81 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen |
Das Unternehmen CULLINAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,21 % bei einem Aktienkurs von 6,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.